Their study reported the use of CCR5 inhibitor and CCL18 monoclonal antibody to double‐block the CCL5‐CCR5 and CCL18‐PIPTNM3 pathways, which led to significant suppression of tumor metastasis.29 This evidence concerns the gene CCL18 and neoplasm.